TF and prostate cancer: The clotting time of pooled plasma was prolonged by adding anti-TF antibody only in experiments with EVs from DIC patients (p = 0.003), and no significant prolongation of clotting time was observed after adding EVs from prostate cancer patients without DIC (p = 0.734) and EVs from healthy individuals (p = 0.199, Table 2, Figure 3B).